172 related articles for article (PubMed ID: 29564390)
1. Bone targeting compounds for radiotherapy and imaging: *Me(III)-DOTA conjugates of bisphosphonic acid, pamidronic acid and zoledronic acid.
Meckel M; Bergmann R; Miederer M; Roesch F
EJNMMI Radiopharm Chem; 2017; 1(1):14. PubMed ID: 29564390
[TBL] [Abstract][Full Text] [Related]
2. Preliminary results of biodistribution and dosimetric analysis of [
Khawar A; Eppard E; Roesch F; Ahmadzadehfar H; Kürpig S; Meisenheimer M; Gaertner FC; Essler M; Bundschuh RA
Ann Nucl Med; 2019 Jun; 33(6):404-413. PubMed ID: 30877560
[TBL] [Abstract][Full Text] [Related]
3.
Pfannkuchen N; Bausbacher N; Pektor S; Miederer M; Rosch F
Curr Radiopharm; 2018; 11(3):223-230. PubMed ID: 29866026
[TBL] [Abstract][Full Text] [Related]
4. (177)Lu-labelled macrocyclic bisphosphonates for targeting bone metastasis in cancer treatment.
Bergmann R; Meckel M; Kubíček V; Pietzsch J; Steinbach J; Hermann P; Rösch F
EJNMMI Res; 2016 Dec; 6(1):5. PubMed ID: 26780082
[TBL] [Abstract][Full Text] [Related]
5. In vivo comparison of DOTA based 68Ga-labelled bisphosphonates for bone imaging in non-tumour models.
Meckel M; Fellner M; Thieme N; Bergmann R; Kubicek V; Rösch F
Nucl Med Biol; 2013 Aug; 40(6):823-30. PubMed ID: 23915801
[TBL] [Abstract][Full Text] [Related]
6. A DOTA based bisphosphonate with an albumin binding moiety for delayed body clearance for bone targeting.
Meckel M; Kubíček V; Hermann P; Miederer M; Rösch F
Nucl Med Biol; 2016 Nov; 43(11):670-678. PubMed ID: 27560354
[TBL] [Abstract][Full Text] [Related]
7. Comparison of sequential planar 177Lu-DOTA-TATE dosimetry scans with 68Ga-DOTA-TATE PET/CT images in patients with metastasized neuroendocrine tumours undergoing peptide receptor radionuclide therapy.
Sainz-Esteban A; Prasad V; Schuchardt C; Zachert C; Carril JM; Baum RP
Eur J Nucl Med Mol Imaging; 2012 Mar; 39(3):501-11. PubMed ID: 22183108
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Safety and Dosimetry of
Fernández R; Eppard E; Lehnert W; Jiménez-Franco LD; Soza-Ried C; Ceballos M; Ribbeck J; Kluge A; Rösch F; Meckel M; Zhernosekov K; Kramer V; Amaral H
J Nucl Med; 2021 Aug; 62(8):1126-1132. PubMed ID: 33419945
[TBL] [Abstract][Full Text] [Related]
9. Novel Radiolabeled Bisphosphonates for PET Diagnosis and Endoradiotherapy of Bone Metastases.
Pfannkuchen N; Meckel M; Bergmann R; Bachmann M; Bal C; Sathekge M; Mohnike W; Baum RP; Rösch F
Pharmaceuticals (Basel); 2017 May; 10(2):. PubMed ID: 28524118
[TBL] [Abstract][Full Text] [Related]
10. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
11. Biodistribution and post-therapy dosimetric analysis of [
Khawar A; Eppard E; Roesch F; Ahmadzadehfar H; Kürpig S; Meisenheimer M; Gaertner FC; Essler M; Bundschuh RA
EJNMMI Res; 2019 Nov; 9(1):102. PubMed ID: 31781962
[TBL] [Abstract][Full Text] [Related]
12. Gallium(III) complexes of NOTA-bis (phosphonate) conjugates as PET radiotracers for bone imaging.
Holub J; Meckel M; Kubíček V; Rösch F; Hermann P
Contrast Media Mol Imaging; 2015; 10(2):122-34. PubMed ID: 24801892
[TBL] [Abstract][Full Text] [Related]
13. Theranostic Agent Targeting Bone Metastasis: A Novel [
Jin W; Zhao R; Wang R; Choi SR; Ploessl K; Alexoff D; Wu Z; Zhu L; Kung HF
J Med Chem; 2024 Mar; 67(6):4793-4803. PubMed ID: 38450559
[TBL] [Abstract][Full Text] [Related]
14. Safety and Efficacy of 68 Ga- or 177 Lu-Labeled DOTA-IBA as a Novel Theranostic Radiopharmaceutical for Bone Metastases : A Phase 0/I Study.
Qiu L; Wang Y; Liu H; Wang Q; Chen L; Liu L; Wang L; Feng Y; Chen Y
Clin Nucl Med; 2023 Jun; 48(6):489-496. PubMed ID: 36976706
[TBL] [Abstract][Full Text] [Related]
15. Development of Fibroblast Activation Protein Inhibitor-Based Dimeric Radiotracers with Improved Tumor Retention and Antitumor Efficacy.
Zhao L; Chen J; Pang Y; Fang J; Fu K; Meng L; Zhang X; Guo Z; Wu H; Sun L; Su G; Lin Q; Chen H
Mol Pharm; 2022 Oct; 19(10):3640-3651. PubMed ID: 35917335
[TBL] [Abstract][Full Text] [Related]
16. DOTA-PESIN, a DOTA-conjugated bombesin derivative designed for the imaging and targeted radionuclide treatment of bombesin receptor-positive tumours.
Zhang H; Schuhmacher J; Waser B; Wild D; Eisenhut M; Reubi JC; Maecke HR
Eur J Nucl Med Mol Imaging; 2007 Aug; 34(8):1198-208. PubMed ID: 17262215
[TBL] [Abstract][Full Text] [Related]
17. Influence of a novel, versatile bifunctional chelator on theranostic properties of a minigastrin analogue.
Pfister J; Summer D; Rangger C; Petrik M; von Guggenberg E; Minazzi P; Giovenzana GB; Aloj L; Decristoforo C
EJNMMI Res; 2015 Dec; 5(1):74. PubMed ID: 26669693
[TBL] [Abstract][Full Text] [Related]
18. A new class of PentixaFor- and PentixaTher-based theranostic agents with enhanced CXCR4-targeting efficiency.
Osl T; Schmidt A; Schwaiger M; Schottelius M; Wester HJ
Theranostics; 2020; 10(18):8264-8280. PubMed ID: 32724470
[TBL] [Abstract][Full Text] [Related]
19.
Liu F; Zhu H; Yu J; Han X; Xie Q; Liu T; Xia C; Li N; Yang Z
Tumour Biol; 2017 Jun; 39(6):1010428317705519. PubMed ID: 28618966
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]